{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"semaglutide-glp1-gut","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide-glp1-gut/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/semaglutide-glp1-gut/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide-glp1-gut/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide-glp1-gut/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide-glp1-gut/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide-glp1-gut/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/semaglutide-glp1-gut/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"semaglutide-glp1-gut","title":"Semaglutide and GLP-1 Gut Damage: Evidence on Gastroparesis Risks, Metabolic Effects, and Tradeoffs","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:41:45.687Z","body_excerpt":"## What's breaking down if you have GLP-1 gut damage / gastroparesis\n\nGLP-1 gut damage, often called medication-induced gastroparesis or delayed gastric emptying, occurs when GLP-1 receptor agonists slow stomach motility. This is an intended mechanism for appetite control and blood sugar regulation. The result is food staying in the stomach longer than normal.\n\nIf you have this issue, the primary layer breaking down is gastric motility. Stomach muscles and nerves respond less effectively to signals that move contents forward. In some cases, symptoms persist after stopping the drug, suggesting possible lingering effects on the enteric nervous system or smooth muscle function.\n\nA secondary layer is overall gut signaling. Early satiety turns into nausea, vomiting, bloating, or pain when emptying is too slow. Rapid weight loss from these drugs can add metabolic stress, though the direct gut effect comes from the agonist action itself.\n\nRegeneration here means restoring normal gastric emptying rates and nerve signaling. Degeneration means ongoing slowed motility outrunning the gut's ability to recover normal function. Human data show this effect is tied to the drug class rather than permanent structural destruction in most reported cases.\n\n## Why Semaglutide might help you\n\n1. You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name.\n2. **What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\n3. **What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\n4. **Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nIf your GLP-1 gut symptoms coexist with excess body weight that adds compressive force to the spine and joints (roughly 4 lb lumbar load per extra pound carried), semaglutide's studied weight-loss pathway could indirectly ease that mechanical burden. The gut slowing remains the direct tradeoff of the same mechanism.\n\n## Why GLP-1 agonists (class) matters for you\n\n**Drug:** GLP-1 agonists (class)\n\n**What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\n\n**Therefore for you:** GLP-1 agonists support metabolism and promote weight loss that reduces mechanical load on weight-bearing tissues. However, they suppress normal gastric emptying signals as the core mechanism, which directly contributes to or causes the gut damage/gastroparesis layer. For someone already experiencing this condition, the class trades metabolic and load-reduction gains against further slowing of gut motility and potential delayed recovery of normal emptying. The net effect on repair is mixed: body composition improves while gut function faces added suppression.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Semaglutide** → metabolic load / body weight\n\nSemaglutide as the specific GLP-1 agonist drives both the metabolic benefits (weight reduction that eases tissue load) and the gut-slowing effect. The class-level tradeoff applies directly to semaglutide use. No separate peptides are in scope here, so the discussion centers on this one agent's dual impact: load reduction alongside motility suppression.\n\n## What the evidence actually shows\n\nHuman trials and observational data form the main evidence base. A 2023 JAMA cohort study of patients using GLP-1 agonists for weight loss found a significantly elevated risk of gastroparesis diagnosis compared with bupropion-naltrexone users (adjusted HR 3.67, 95% CI 1.15-11.90). The study used insurance claims data and excluded patients with prior diabetes in the main analysis. Incidence remained low overall (under 1-2% in most cohorts) but the relative risk increase was c","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"GLP-1 agonists including semaglutide slow gastric emptying as an on-target mechanism.","tier":"human","weight":0.8,"section":"What's breaking down if you have GLP-1 gut damage / gastroparesis","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes the direct link between the drug class and the condition described.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c3","text":"Case reports show symptom resolution and normalized gastric emptying studies after semaglutide discontinuation in multiple patients.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1","s2"],"source_status":"sourced","why_material":"Documents observed reversibility in real-world human cases.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c2","text":"A 2023 JAMA study found GLP-1 agonist use for weight loss associated with increased gastroparesis risk (adjusted HR 3.67 vs bupropion-naltrexone).","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s0"],"source_status":"sourced","why_material":"Provides the primary human observational evidence on risk elevation.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c4","text":"Reddit users report variable recovery timelines after stopping semaglutide, ranging from weeks to persistent symptoms beyond 6 months.","tier":"anecdotal","weight":0.3,"section":"What people say on Reddit","slot":null,"interaction_risk":false,"status":"active","source_ids":["s24","s25"],"source_status":"sourced","why_material":"Captures patient-reported outcomes separate from controlled data.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s0","type":"pubmed","url":"https://jamanetwork.com/journals/jama/fullarticle/2810542","title":"GLP-1 Agonists and Gastrointestinal Adverse Events","quote":"Use of GLP-1 agonists compared with bupropion-naltrexone was associated with increased risk of ... gastroparesis (HR, 3.67 [95% CI, 1.15-11.90])","summary":"Cohort study using claims data showing elevated gastroparesis risk with GLP-1 agonists for weight loss.","claim_ids":["c2"],"link_status":"http_403","quote_status":"unverified","hash":"46b470ae8f3ed42b061633f5f6e9c8081c4842468a91ea10514c6a442f8be95e"},{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10874596/","title":"Tendency of Semaglutide to Induce Gastroparesis: A Case Report","quote":"The patient reported significant improvement in symptoms at one-month follow-up after stopping semaglutide, with complete resolution of nausea.","summary":"Case report documenting resolution after discontinuation.","claim_ids":["c1","c3"],"link_status":"ok","quote_status":"verified","hash":"9e3ac56c1c1b3d8eb2e4e7f0e7ce2615b3ce564986c01573effee2357817d18e"},{"id":"s2","type":"medical","url":"https://www.gastroenterologyadvisor.com/features/what-we-know-about-semaglutide-adverse-events-and-gastroparesis-part-1/","title":"What We Know About Semaglutide Adverse Events and Gastroparesis","quote":"A 4-hour scintigraphic gastric emptying (SGE) test indicated delayed gastric emptying. Semaglutide was held for 6 weeks, leading to symptom resolution.","summary":"Review of adverse event data and case examples of resolution.","claim_ids":["c3"],"link_status":"dead","quote_status":"unverified","hash":"946805350c24bae7564cd931e6de493739e5cc007ccde0a89b1c852eef37a291"},{"id":"s24","type":"reddit","url":"https://www.reddit.com/r/Gastroparesis/comments/1ld2qf9/ozempic_has_changed_my_life_forever_for_the_worst/","title":"Ozempic has changed MY LIFE forever. For the worst","quote":"The thing about Ozempic and other GLP's is that it actually causes symptoms of gastroparesis as a mechanism for promoting weight loss.","summary":"User discussion on mechanism and outcomes.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"200b3307a256252c7feb97753d258ae510b351fa6c8223e4d739d3030cac23c0"},{"id":"s25","type":"reddit","url":"https://www.reddit.com/r/Gastroparesis/comments/1jbssgb/i_stopped_my_ozempic_when_do_i_get_my_stomach/","title":"I stopped my Ozempic. When do I get my stomach back?","quote":"It took about 2 months to get to about 80 percent better for me.","summary":"Recovery timeline anecdotes.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"eb5e496026dc3f916414ab4ef4e8adaa1a570a0d16aa1f4a00a1cff2160a1646"}],"anecdotal_sources":[{"id":"s24","type":"reddit","url":"https://www.reddit.com/r/Gastroparesis/comments/1ld2qf9/ozempic_has_changed_my_life_forever_for_the_worst/","title":"Ozempic has changed MY LIFE forever. For the worst","quote":"The thing about Ozempic and other GLP's is that it actually causes symptoms of gastroparesis as a mechanism for promoting weight loss.","summary":"User discussion on mechanism and outcomes.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"200b3307a256252c7feb97753d258ae510b351fa6c8223e4d739d3030cac23c0"},{"id":"s25","type":"reddit","url":"https://www.reddit.com/r/Gastroparesis/comments/1jbssgb/i_stopped_my_ozempic_when_do_i_get_my_stomach/","title":"I stopped my Ozempic. When do I get my stomach back?","quote":"It took about 2 months to get to about 80 percent better for me.","summary":"Recovery timeline anecdotes.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"eb5e496026dc3f916414ab4ef4e8adaa1a570a0d16aa1f4a00a1cff2160a1646"}],"scientific_sources":[{"id":"s0","type":"pubmed","url":"https://jamanetwork.com/journals/jama/fullarticle/2810542","title":"GLP-1 Agonists and Gastrointestinal Adverse Events","quote":"Use of GLP-1 agonists compared with bupropion-naltrexone was associated with increased risk of ... gastroparesis (HR, 3.67 [95% CI, 1.15-11.90])","summary":"Cohort study using claims data showing elevated gastroparesis risk with GLP-1 agonists for weight loss.","claim_ids":["c2"],"link_status":"http_403","quote_status":"unverified","hash":"46b470ae8f3ed42b061633f5f6e9c8081c4842468a91ea10514c6a442f8be95e"},{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10874596/","title":"Tendency of Semaglutide to Induce Gastroparesis: A Case Report","quote":"The patient reported significant improvement in symptoms at one-month follow-up after stopping semaglutide, with complete resolution of nausea.","summary":"Case report documenting resolution after discontinuation.","claim_ids":["c1","c3"],"link_status":"ok","quote_status":"verified","hash":"9e3ac56c1c1b3d8eb2e4e7f0e7ce2615b3ce564986c01573effee2357817d18e"},{"id":"s2","type":"medical","url":"https://www.gastroenterologyadvisor.com/features/what-we-know-about-semaglutide-adverse-events-and-gastroparesis-part-1/","title":"What We Know About Semaglutide Adverse Events and Gastroparesis","quote":"A 4-hour scintigraphic gastric emptying (SGE) test indicated delayed gastric emptying. Semaglutide was held for 6 weeks, leading to symptom resolution.","summary":"Review of adverse event data and case examples of resolution.","claim_ids":["c3"],"link_status":"dead","quote_status":"unverified","hash":"946805350c24bae7564cd931e6de493739e5cc007ccde0a89b1c852eef37a291"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"semaglutide-glp1-gut","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":4,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":4,"claims_total":4,"sources":5,"anecdotal":2,"scientific":3,"user_reports":0,"questions":0,"evidence_ingests":0}}